The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%

FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%

September 15, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On July 15, the U.S. Food & Drug Administration (FDA) approved a 10% solution of an intravenous human immunoglobulin (IVIG), Octagam 10%, to treat adults with dermatomyositis. This approval was based on results of the Progress in Dermatomyositis (ProDERM) study (NCT02728752).1–3

You Might Also Like
  • FDA Approves IVIG to Treat Adults with Dermatomyositis
  • EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
  • FDA Enforcement Against Injectable Colchicine
Also By This Author
  • 3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

More recently, the FDA Office of Orphan Products Development granted Octapharma, the manufacturer of Octagam 10%, seven years of marketing exclusivity for this product, which is the first and only IVIG treatment for adult dermatomyositis.4 The FDA grants orphan drug status to unique therapeutic agents intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect less than 200,000 residents of the U.S.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the treatment of dermatomyositis, Octagam 10% should be administered at a dose of 2 g/kg divided equally and given over two–five consecutive days every four weeks. The initial infusion rate should be 1 mg/kg/min (0.01 mL/kg/min) up to a maintenance infusion rate of 4 mg/kg/min (up to 0.04 mL/kg/min), if tolerated.

The intravenous IVIG solution is also FDA approved to treat chronic immune thrombocytopenic purpura (ITP) in adults.5

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Boxed Warning

For all indications, Octagam 10% carries a boxed warning, noting risks of thrombosis, renal dysfunction and acute renal failure. Risk factors for developing thrombosis include advanced age, a history of venous or arterial thrombosis, hypercoagulable conditions, hyperviscosity, prolonged immobilization, indwelling vascular catheters, use of estrogens and cardiovascular risk factors. When IVIG is administered in predisposed patients, acute renal failure, osmotic nephropathy, renal dysfunction and death can occur. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products that contain sucrose. However, Octagam 10% does not contain sucrose.

To prevent thrombosis, renal dysfunction or renal failure, Octagam 10% should be administered at the lowest possible infusion rate. Patients should be adequately hydrated prior to administration and should be monitored for signs and symptoms of thrombosis. Blood viscosity should be assessed in patients at risk for hyperviscosity.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Biologics license 125062/234; July 11, 2014. Supporting documents older than three years—Octagam. U.S. Food & Drug Administration.
  2. Supplemental biologics license approval letter Octagam. U.S. Food & Drug Administration. 2021 Jul 15.
  3. Aggarwal R, Charles-Schoeman C, Schessl J, et al. A randomized, double-blind, placebo-controlled phase 3 trial of IVIG 10% in patients with dermatomyositis, the ProDERM study: Results on efficacy and safety [abstract OP0008]. Ann Rheum Dis. 2021;80:4–5.
  4. News release: FDA orphan drug approval—Octapharma’s Octagam 10% receives 7 years of market exclusivity for adult dermatomyositis. Octapharma AG. 2021 Aug. 30.
  5. Highlights of prescribing information: Octagam 10%, immune globulin intravenous (human). U.S. Food & Drug Administration. 2021 July 15.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Pharma Co. News Tagged With: dermatomyositis, dermatomyositis (DM), FDA, FDA approval, intravenous human immunoglobulin, IVIg, Octagam 10%, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves IVIG to Treat Adults with Dermatomyositis
  • EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
  • FDA Enforcement Against Injectable Colchicine
  • FDA Approves Drug for Lambert-Eaton Myasthenic Syndrome

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)